ArticleCancer imaging : the official publication of the International Cancer Imaging Society2025
Investigation into the efficiency and prognostic elements of CT-guided ¹²⁵I particle implantation for liver cancer.
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Combined imaging and serum biomarkers in CEUS-guided microwave ablation for hepatocellular carcinoma: A meta-analysis.Frontiers in oncology · 2025Pooled it
- Seven-year follow-up demonstrating sustained survival followingOncology letters · 2026Article
- Gut Microbiota Dysbiosis MediatesImmunity, inflammation and disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeThis study assessed the effectiveness and prognostic factors of CT-guided ¹²⁵I seed implantation for primary hepatocellular carcinoma (HCC).
methodsA retrospective analysis of 71 patients (57 males, 14 females, median age 64) treated at three Chinese hospitals from 2018 to 2024 was conducted. The main outcomes were local progression-free survival (LPFS) and overall survival (OS). Treatment involved a 16-slice Spiral CT and Radioactive Particle Treatment Planning System (TPS), with seeds of 18.5-29.6 MBq implanted via freehand puncture. Efficacy was evaluated using the modified Response Evaluation Criteria in Solid Tumors (mRECIST) at three months, with follow-ups every three months for three years, then biannually until December 2024. Data analysis utilized SPSS 22.0, Kaplan-Meier, and Cox models.
resultsWith a median follow-up of 37 months, the complete response (CR) rate was 57.7%, partial response (PR) 31.0%, stable disease (SD) 5.6%, and progressive disease (PD) 5.6%. Local control was 94.3%. LPFS rates at 1, 3, and 5 years were 74.6%, 29.5%, and 1.4% (median LPFS 22 months), while overall survival (OS) rates were 88.7%, 47.8%, and 12.6% (median OS 35 months). CR was a key protective factor for LPFS and OS. Significant factors included the Barcelona Clinic Liver Cancer (BCLC) stage C, intrahepatic progression, and extrahepatic metastasis. Postoperative complications occurred in 35.2% of patients, with no severe cases.
conclusionCT-guided ¹²⁵I seed implantation is effective and safe for primary HCC, with CR being crucial for survival. Large-scale studies are needed to confirm these results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.